VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond
VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand graphic processing capabilities for a wide range of embedded applications. As one of the first providers of 3D GPU technology for the LVGL ecosystem, VeriSilicon will contribute to advancing 3D rendering capabilities within the LVGL library.
LVGL is the most popular free and open-source embedded graphics library to create beautiful User Interfaces (UIs) for any Microcontroller Units (MCUs), Micro Processor Units (MPUs), or display type. By integrating VeriSilicon’s low-power and high-performance GPU solutions into LVGL’s graphics ecosystem, it offers developers the ability to rapidly deliver improved visual experiences, while maintaining power efficiency on compact, resource-constrained devices.
Actions Technology, a low-power AIoT fabless semiconductor company, is among the first to adopt this integrated solution in their smart watch System-on-Chips (SoCs). The company recognizes the potential of VeriSilicon’s low-power GPU technology, which, in conjunction with LVGL’s graphics library, will enhance the user experience of next-generation wearable devices.
Gabor Kiss-Vamosi, CEO of LVGL, said, “VeriSilicon’s VGLite 2.5D GPU technology has pioneered a new era in the embedded world, enabling complex vector graphics with exceptional speed and low power consumption. Now, we stand at the edge of a new revolution: the arrival of 3D GPUs to MCUs. This breakthrough will transform the embedded UI landscape, unlocking never-before-seen possibilities for user interfaces on small, resource-constrained, and battery-powered devices. At LVGL, we are excited to embrace this technology and harness its potential across a wide range of platforms. Our goal is to provide a great developer experience for VeriSilicon’s 3D GPUs, enabling seamless integration of 2D, 2.5D, and 3D content that will no doubt lead to some remarkable embedded applications.”
Tim Zhang, Wearable and Sensing Business Unit General Manager of Actions Technology, said, “LVGL’s flexible and powerful graphics solutions are essential to enhance the user interfaces of our wearable products. As the wearable industry embraces 3D graphics, the adoption of VeriSilicon’s powerful and energy-efficient technologies enables us to push the boundaries of innovation, delivering rich 3D graphics with low power consumption.”
“Wearable products are experiencing rapid growth, offering extended functionalities that go far beyond traditional watches. They have evolved into accessible information devices with integrated health monitoring features,” said Weijin Dai, Executive Vice President and General Manager of VeriSilicon’s IP Division. “With this growth, delivering a powerful user interface to effectively communicate information on small displays, while maintaining low power consumption, has become essential. At VeriSilicon, we work closely with our customers to integrate 3D GPU technology into their next-generation products. As a leading provider of wearable GPUs for both 2.5D and 3D applications, we collaborate with LVGL and partners like Actions to drive innovation and achieve this mission.”
About LVGL
LVGL Kft. is the creator of LVGL, the leading free and open-source graphics library for embedded systems, enabling high-quality UIs on any Microcontroller Unit (MCU), Micro Processor Unit (MPU), or display type. With a global community and industry partnerships, LVGL empowers developers to build visually rich, responsive, and efficient UIs for resource-constrained devices from wearables to industrial equipment. For more information, visit www.lvgl.io.
About Actions Technology
Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com.
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128646659/en/
Contacts
Media Contact:
press@verisilicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 09:00:00 EET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 09:00:00 EET | Press release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 09:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 23:05:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 19:43:00 EET | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom